Research tools · Antibody discovery software
PipeBio
A five person Danish company that built cloud bioinformatics for antibody discovery, got its name into the methods sections of twenty published papers, and was bought by Benchling in October 2024.
One sentence in a Nature methods section
In May 2026 Nature published a paper on cell type targeted mitochondrial transplantation, from the Institute of Molecular and Clinical Ophthalmology Basel and ETH Zurich. Deep in the methods, between a phage display protocol and a surface plasmon resonance run, sits a single line: “Data analysis was performed using the PipeBio platform.”
That sentence is close to the whole company. PipeBio never ran a clinical trial, never filed with the FDA, never took an NIH or NSF award. What it accumulated instead is a line in other people’s methods sections. A full text search of PubMed Central on September 24, 2026 returns twenty articles that name it, dated 2023 to 2026, in Nature, Nature Communications, Science advances, Antibody therapeutics, Protein science, Cell reports methods and eight other journals.
The labs doing the citing are not a narrow cluster. KTH Royal Institute of Technology in Stockholm appears repeatedly. So do the Walter and Eliza Hall Institute in Melbourne, the La Jolla Institute for Immunology, KU Leuven in Belgium, Orion Corporation in Finland, Twist Bioscience, Tavotek Biotherapeutics, and Confo Therapeutics in Ghent.
The bottleneck the software was pointed at
Modern antibody discovery produces sequences by the million. A team runs four rounds of phage panning, sequences the output, and then needs to know which clones enriched, which cluster together, which carry manufacturing liabilities, and which are worth expressing. For most labs that meant waiting for a bioinformatician, or building a pipeline in house.
PipeBio’s premise was that the scientist should not have to wait. Its own description, filed with Y Combinator, ends on the point: “We believe that science moves faster when scientists can curate and analyse their own data.” The product merged paired end reads, annotated germlines, clustered clonotypes, screened liabilities and overlaid assay data, in a browser, with an API for teams wiring it into a LIMS.
Two men out of the Geneious world
Jannick Bendtsen holds a PhD in bioinformatics from the Technical University of Denmark. Before PipeBio he worked at CLC bio, later bought by Qiagen, at Cartagenia, later bought by Agilent, and at Biomatters, the New Zealand company behind Geneious. A conference biography credits him with “nearly 20 years of experience in highly successful bioinformatics companies such as CLC bio and Geneious”. Owen Bodley, the technical co-founder, also worked at Biomatters. That is where the two met, and the company they went on to build competes most directly with Geneious Biologics, now part of Dotmatics.
Customers arrived before the capital did
Isogenica, a UK single domain antibody company, said in September 2021 it was deploying the platform against its synthetic VHH libraries. TrueBinding followed in July 2022 with a hybridoma workflow, and Abalone Bio in October 2022. In April 2024 Bruker Cellular Analysis published a study pairing PipeBio analysis with its Beacon optofluidic instrument.
The Danish filed accounts show the same curve from the other side. Trade receivables were DKK 69,000 at the end of 2021, DKK 95,000 at the end of 2022, and DKK 1,483,000 at the end of 2023. Danish small company accounts need not disclose turnover, so receivables are the closest available proxy, and they rose roughly fifteenfold in one year. Losses rose too: DKK 2.4 million, 2.7 million and 2.8 million across the same three years, ending 2023 with equity of minus DKK 7.8 million. The company had five employees.
Sold
Benchling announced the acquisition on October 20, 2024, and was specific about how the two met: “Over the last three years, we got to know the PipeBio team, led by its founders, Jannick Bendtsen and Owen Bodley, through Benchling’s Developer Program.” PipeBio had built an integration first and sold into shared customers. Mazanti-Andersen, a Copenhagen law firm, advised the sellers. No price has been published. Nine months later the Danish trade title KapitalWatch reported that the sale had made both founders multi millionaires, and quoted one of them on the proceeds: “Noget af det skal investeres, og noget af det bliver selvfølgelig også brugt personligt”.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Methods citations | 20 articles in PubMed Central name PipeBio as of Sep 24, 2026, dated 2023 to 2026. One is indexed in PubMed itself. Journals include Nature, Nature Communications and Science advances. | Public record |
| How it is cited | Named as a tool with the vendor address, not as a collaborator. Examples: “PipeBio (PipeBio ApS, Horsens, DK)”, “analyzed with PipeBio (Horsens, Denmark)”, and “PipeBio software suite (PipeBio)” beside Qiagen CLC Main Workbench in a Confo Therapeutics paper. | Public record |
| Staff named in a paper | A 2023 Antibody therapeutics paper from Twist Bioscience thanks four PipeBio staff plus both founders for repertoire pipeline analysis. | Public record |
| Named customers | Isogenica (Sep 2021), TrueBinding (Jul 2022) and Abalone Bio (Oct 2022), each with a named scientist quoted. No contract values disclosed. | Partner-stated |
| Danish filed accounts | CVR 41043288. Gross profit DKK 979k (2020), minus 183k (2021), 349k (2022), 559k (2023). Losses of DKK 2.4m, 2.7m and 2.8m across 2021 to 2023. Equity minus DKK 7.8m at end 2023. Five employees. | Public record |
| Total capital raised | PitchBook says $316K across two accelerator cheques and a seed round. CB Insights says $130K. Dealroom lists a single $125k seed. The three do not reconcile, and no filing settles it. | Sources disagree |
| Headquarters | The company register, PitchBook and CB Insights all give Horsens. LinkedIn and Y Combinator give Aarhus. Press releases are datelined Horsens. | Sources disagree |
| The speed claim | Its lead investor describes a platform that “accelerates the creation of therapeutics 10x faster”. No benchmark, study or customer time saving has been published to support the figure. | Not evidenced |
| Belgian entity | No Belgian registration or office was found in the public record. The Belgian link is on the customer side: Confo Therapeutics in Ghent and KU Leuven both name the software in published methods. | Not found |
Read plainly: the usage record is real, independently verifiable and unusually good for a company this small. The commercial record is thin by design, because a Danish ApS of five people need not publish turnover. What the accounts do show is a company still losing money and carrying negative equity in the year before it sold.
What to watch
- Whether the PipeBio name survives inside Benchling. It is still a product name on benchling.com, and a 2025 paper already cites the tool as “PipeBio software (PipeBio/Benchling)”.
- The methods citation count. Twenty papers in under four years is the clearest proxy for adoption, and the one number nobody can spin.
- On premise deployment. A February 2026 competitor comparison claims that “users at large pharmaceutical companies have reported that the lack of an on-premise solution is a deal-breaker for their data security requirements”.
- The Danish entity itself. Its registered address has moved to a corporate services address in Copenhagen and its board chair is now listed as Ronald Scott Gill.
In their words
“no-code bioinformatics is the missing piece with the power to merge two revolutions: in-silico life science, and engineering tools for non-coders.”
Torsten Kolind, byFounders Collective member, in the fund’s investment note, 2021 · Investor
“For Isogenica one of the great strengths of the PipeBio platform is the ease with which we can rapidly characterise our synthetic antibody libraries, as well as associate functional data to deep sequencing data from selection outputs.”
Simon Cooper, Senior Scientist II, Isogenica, September 2021 · Partner release
“We use PipeBio’s platform for everything from sequence analysis and data visualization to storage of NGS data and hit-picked sequences all from our hybridoma sequencing work.”
Parastu Nejad, Research Associate, TrueBinding, July 2022 · Partner release
“PipeBio’s workflow is easy to use for members of our team across the full range of computational experience, making NGS-based antibody library and enrichment analyses accessible while still remaining powerful and flexible.”
Richard Yu, CEO and co-founder, Abalone Bio, October 2022 · Partner release
“Owen Bodley and Jannick Bendtsen (affiliation: PipeBio ApS, Denmark) for their help with repertoire pipeline analysis and the associated figures.”
Acknowledgments, Twist Bioscience authors, Antibody therapeutics, 2023 · Peer reviewed
“Some of the leading pharmaceutical and biotech companies are among PipeBio’s initial customers.”
byFounders investment note, 2021, naming none of them · Investor
Related companies
Sources
- Public recordPipeBio ApS, CVR 41043288, register entry and filed accounts 2020 to 2023
- Public recordPipeBio ApS company record and key figures
- Public recordPubMed Central full text search for PipeBio, 20 articles
- Public recordCell-type-targeted mitochondrial transplantation rescues cell degeneration
- Public recordStructure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist
- Public recordAlpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform
- IndependentDanish startup joins US-based Benchling
- IndependentSalg til amerikanere har gjort Pipebio-stiftere til mangemillionærer
- IndependentPipeBio company profile, funding and investor list
- IndependentPipeBio products, competitors and financials
- IndependentAn Integrated Approach with the Beacon Platform and PipeBio
- IndependentPlatforma vs. Geneious vs. PipeBio
- InvestorWhy We Invested in PipeBio
- CompanyBenchling acquires PipeBio to accelerate AI-powered antibody discovery
- PartnerIsogenica announce deployment of the PipeBio Bioinformatic Cloud
- PartnerTrueBinding and PipeBio announce ongoing collaboration
- PartnerAbalone Bio and PipeBio announce collaborative efforts
- CompanyPipeBio product, about and listing pages
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
